Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
Prerna Arora, Lu Zhang, Nadine Krüger, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 8, pp. 1103-1111.e6
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
Panke Qu, Julia N. Faraone, John P. Evans, et al.
Cell Reports (2023) Vol. 42, Iss. 5, pp. 112443-112443
Open Access | Times Cited: 145
Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
Prerna Arora, Amy Kempf, Inga Nehlmeier, et al.
The Lancet Infectious Diseases (2022) Vol. 23, Iss. 1, pp. 22-23
Open Access | Times Cited: 142
Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages
Shuai Xia, Lijue Wang, Yun Zhu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 134
Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?
Manish Dhawan, AbdulRahman A. Saied, Saikat Mitra, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 154, pp. 113522-113522
Open Access | Times Cited: 93
Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection
Lin Yao, Ka-Li Zhu, Xiaolin Jiang, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 8, pp. 1116-1117
Open Access | Times Cited: 71
SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency
Lu Zhang, Amy Kempf, Inga Nehlmeier, et al.
Cell (2024) Vol. 187, Iss. 3, pp. 596-608.e17
Closed Access | Times Cited: 71
Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination
Metodi V. Stankov, Markus Hoffmann, Rodrigo Gutierrez Jauregui, et al.
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 1, pp. e1-e3
Open Access | Times Cited: 47
Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
Panke Qu, Julia N. Faraone, John P. Evans, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 42
Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines
Rupsha Fraser, Aurelio Orta‐Resendiz, Alexander Mazein, et al.
Trends in Molecular Medicine (2023) Vol. 29, Iss. 4, pp. 255-267
Open Access | Times Cited: 33
Omicron subvariant BA.5 efficiently infects lung cells
Markus Hoffmann, Lok-Yin Roy Wong, Prerna Arora, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 30
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 7
Continued evasion of neutralizing antibody response by Omicron XBB.1.16
Julia N. Faraone, Panke Qu, Yi-Min Zheng, et al.
Cell Reports (2023) Vol. 42, Iss. 10, pp. 113193-113193
Open Access | Times Cited: 19
Immune Evasion of SARS-CoV-2 Omicron Subvariants
Hanzhong Ke, Matthew Chang, Wayne A. Marasco
Vaccines (2022) Vol. 10, Iss. 9, pp. 1545-1545
Open Access | Times Cited: 26
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2
Lia Fiaschi, Filippo Dragoni, Elisabetta Schiaroli, et al.
Viruses (2022) Vol. 14, Iss. 7, pp. 1374-1374
Open Access | Times Cited: 22
Omicron BA.2 Lineage, the “Stealth” Variant: Is It Truly a Silent Epidemic? A Literature Review
Giorgio Tiecco, Samuele Storti, Stefania Arsuffi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7315-7315
Open Access | Times Cited: 22
SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies
Anna L. Beukenhorst, Clarissa M. Koch, Christoforos Hadjichrysanthou, et al.
European Journal of Epidemiology (2023) Vol. 38, Iss. 3, pp. 237-242
Open Access | Times Cited: 12
Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab
Clara Luzia Magnus, Andreas Hiergeist, Philipp Schuster, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 20
Molecular dynamics studies reveal structural and functional features of the SARS‐CoV‐2 spike protein
Ludovico Pipitò, Roxana‐Maria Rujan, Christopher A. Reynolds, et al.
BioEssays (2022) Vol. 44, Iss. 9
Open Access | Times Cited: 19
Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
Xuejun Wang, Lin Yao, Hong‐Yun Zhang, et al.
Genome Medicine (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 19
The XBB.1.5 slightly increase the binding affinity for host receptor ACE2 and exhibit strongest immune escaping features: molecular modeling and free energy calculation
Muhammad Suleman, Aneela Murtaza, Haji Muhammad Shoaib Khan, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 11
A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation
Saskia C. Stein, Guido Hansen, George Ssebyatika, et al.
Journal of Virology (2024)
Open Access | Times Cited: 3
Comparative Study of the Mutations Observed in the SARS-CoV-2 RBD Variants of Concern and Their Impact on the Interaction with the ACE2 Protein
Mariem Ghoula, Audrey Deyawe Kongmeneck, Rita Eid, et al.
The Journal of Physical Chemistry B (2023) Vol. 127, Iss. 40, pp. 8586-8602
Open Access | Times Cited: 8
Neutralization of distinct Omicron sublineages by longitudinal vaccination sera
Xun Wang, Xiaoyu Zhao, Yuchen Cui, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 11, pp. 5090-5092
Closed Access | Times Cited: 11
Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
Hye‐Kyung Lee, Ludwig Knabl, Mary Walter, et al.
iScience (2022) Vol. 25, Iss. 11, pp. 105369-105369
Open Access | Times Cited: 11
Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library
Dmitri Dormeshkin, Michail Shapira, Simon Dubovik, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top